Journal
MOLECULES
Volume 26, Issue 23, Pages -Publisher
MDPI
DOI: 10.3390/molecules26237411
Keywords
Bruton's kinase; (ir)reversible inhibitors; B-cell malignancies; autoimmune diseases; medicinal chemistry; small molecules
Ask authors/readers for more resources
BTK has been a significant target for therapeutic agents in cancer and autoimmune disorders, with both irreversible and reversible inhibitors being developed and investigated. Research on BTK function and inhibitors is of interest for pharmaceutical companies and academia.
Bruton's tyrosine kinase (BTK) represented, in the past ten years, an important target for the development of new therapeutic agents that could be useful for cancer and autoimmune disorders. To date, five compounds, able to block BTK in an irreversible manner, have been launched in the market, whereas many reversible BTK inhibitors (BTKIs), with reduced side effects that are more useful for long-term administration in autoimmune disorders, are under clinical investigation. Despite the presence in the literature of many articles and reviews, studies on BTK function and BTKIs are of great interest for pharmaceutical companies as well as academia. This review is focused on compounds that have appeared in the literature from 2017 that are able to block BTK in an irreversible or reversible manner; also, new promising tunable irreversible inhibitors, as well as PROTAC molecules, have been reported. This summary could improve the knowledge of the chemical diversity of BTKIs and provide information for future studies, particularly from the medicinal chemistry point of view. Data reported here are collected from different databases (Scifinder, Web of Science, Scopus, Google Scholar, and Pubmed) using BTK and BTK inhibitors as keywords.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available